Clinical Trial Update: A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) [Phase 1, Phase 2]

View source ↗

Summary

This document reports on an ongoing Phase 1/2 trial evaluating HBI-002, an oral carbon monoxide–releasing therapeutic, for sickle cell disease, focusing on safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HBI-002

Snippet

Sponsor: Hillhurst Biopharmaceuticals, Inc. | Conditions: Anemia, Sickle Cell | Phase 1, Phase 2 | Status: RECRUITING